Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Adamantinomatous Craniopharyngioma: early-phase trial registry
2 of 2 indexed Recurrent Adamantinomatous Craniopharyngioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Recurrent Adamantinomatous Craniopharyngioma: 2 US clinical trials tracked, 2 recruiting.
Recurrent Adamantinomatous Craniopharyngioma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Nationwide Children's Hospital, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-adamantinomatous-craniopharyngioma
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Recurrent Adamantinomatous Craniopharyngioma lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Adamantinomatous Craniopharyngioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Adamantinomatous Craniopharyngioma is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Nationwide Children's Hospital
NCT05233397
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Nationwide Children's Hospital
NCT05286788
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Adamantinomatous Craniopharyngioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Adamantinomatous Craniopharyngioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Adamantinomatous Craniopharyngioma page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Recurrent Adamantinomatous Craniopharyngioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nationwide Children's Hospital sponsors the most Recurrent Adamantinomatous Craniopharyngioma trials on record, review their full trial history before evaluating a specific study. See Nationwide Children's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Adamantinomatous Craniopharyngioma condition card totals 2 registered trials; most-linked intervention Binimetinib Oral Tablet [Mektovi]; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.